Preclinical Safety
SprayGel has been subjected to all the tests outlined in the U.S. Food and Drug Administration General Program Memorandum #G95-1 entitled, Use of International Standard ISO-10993, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing."

Preclinical Efficacy
SprayGel has been shown to prevent post-surgical abdominopelvic and cardiac adhesion formation in four different preclinical models. More information on preclinical efficacy can be found in the following publications:

• Evaluation in the rat cecum and rabbit uterine horn adhesion models
• Evaluation in a porcine efficacy model

Clinical Efficacy
SprayGel has been evaluated in one European and one US clinical trial to date.